Helix BioPharma Corporation is a Canada-based biopharmaceutical company focused on cancer therapy. It is developing products for the treatment and prevention of cancer based on its technologies. The Company�s product development initiatives have focused on its L-DOS47 and Topical Interferon Alpha-2b new drug candidates. It operates through the biopharmaceuticals segment. The Company�s most advanced product clinically is its Topical Interferon Alpha-2b as a treatment for certain skin/mucosal lesions caused by HPV infections. Its DOS47 is a patented oncology platform technology that offers a new and potentially revolutionary approach to the debilitation and destruction of cancer cells. Its L-DOS47 is a new drug in development that offers an approach to the debilitation and destruction of non-small cell lung cancer cells.